Disclosure of notification received from Mawer

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 5 September 2025 – 5:40 PM CET Disclosure of notification received from MawerPursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from Mawer. Notification by Mawer Investment Management LtdOn 3 September 2025, Fagron received a notification that the shareholding of Mawer Investment Management Ltd, crossed the disclosure...

Rotterdam, 05/09/2025 (informazione.news - comunicati stampa - salute e benessere)

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 5 September 2025 – 5:40 PM CET

Disclosure of notification received from Mawer

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from Mawer.

Notification by Mawer Investment Management Ltd

Further information
Ignacio Artola
Global Investor Relations Leader
investors@fagron.com

About Fagron

Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 35 countries around the world.

The Belgian company Fagron NV is based on Venecoweg 20A in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV. Fagron BV’s head office is located in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment